Zhaoke Ophthalmology Ltd. has announced that the National Medical Products Administration (NMPA) of China has accepted the New Drug Application (NDA) for NVK002 (Atropine Sulphate Eye Drops 0.02%) for the treatment of myopia progression in children. This acceptance marks a significant step in the regulatory review process for this innovative drug, which is being reviewed as a Class II innovative drug. Previously, an Abbreviated New Drug Application (ANDA) for a 0.01% formulation of the same drug was also accepted by the NMPA. The company aims to address the growing issue of myopia among children and adolescents in China, with this development aligning with the national health objectives outlined by the Chinese government.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.